The disclosure provides methods for rescuing defects caused by abnormal CDKL5 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, a muscarinic receptor inhibitor, a GSK3 inhibitor, a Notch inhibitor and any combination thereof. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, CDKL5-mosaic neurospheres, and cortical organoids).
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 25/00 - Drugs for disorders of the nervous system
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
2.
MULTI-RESONANT SWITCHED CAPACITOR POWER CONVERTER ARCHITECTURE
A switched-capacitor (SC) network in an SC converter is controlled to operate at varying resonant modes to achieve high conversion ratio efficiency, at a low circuit component count. These power converters are suited to numerous application areas including improving energy efficiency of data centers. A family of resonant switched capacitor (SC) converters with multiple operating phases are presented “Multi-Resonant SC Converters”. Described in detail are an 8-to-1 Multi-Resonant-Doubler (MRD) converter and a 6-to-1 Cascaded Series-Parallel (CaSP). The topology of these converters make them amenable to combining like units in parallel toward reaching higher power levels.
H02M 3/07 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using resistors or capacitors, e.g. potential divider using capacitors charged and discharged alternately by semiconductor devices with control electrode
H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
H02M 3/158 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load
3.
FUSED QUARTZ DUAL SHELL RESONATOR AND METHOD OF FABRICATION
A dual-shell architecture and methods of fabrication of fused quartz resonators is disclosed. The architecture may include two encapsulated and concentric cavities using plasma-activated wafer bonding followed by the high-temperature glassblowing. The dual-shell architecture can provide a protective shield as well as a “fixed-fixed” anchor for the sensing element of the resonators. Structures can be instrumented to operate as a resonator, a gyroscope, or other vibratory sensor and for precision operation in a harsh environment. Methods for fabricating a dual-shell resonator structure can include pre-etching cavities on a cap wafer, pre-etching cavities on a device wafer, bonding the device wafer to a substrate wafer to form a substrate pair and aligning and bonding the cap wafer to the substrate pair to form a wafer stack with aligned cavities including a cap cavity and a device cavity. The wafer stack may be glassblown to form a dual-shell structure.
G01C 19/5719 - Turn-sensitive devices using vibrating masses, e.g. vibratory angular rate sensors based on Coriolis forces using planar vibrating masses driven in a translation vibration along an axis
B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
H03H 3/007 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks
A method for generating magnetic resonance (MR) images of a kidney region or a brain of a subject using multinuclear magnetic resonance imaging MRI includes performing, using an MRI system, an Na-nuclei pulse sequence module to acquire a portion of a first set of MR data from the kidney or brain region of the subject and performing, using the MRI system, an H-nuclei pulse sequence module to acquire a portion of a second set of MR data from the kidney or brain region of the subject. The Na-nuclei pulse sequence module and the H-nuclei pulse sequence module may be repeated in an interleaved manner until acquisition of the first set of MR data and the second set of MR data are complete. The method further includes generating at least one Na-based image using the first set of MR data, generating at least one H-based image using the second set of MR data and displaying one or more of the at least one Na-based image and the at least one H-based image on a display.
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A magnetic field sensor which can achieve sensitivities competitive with modern sensors while simultaneously maintaining a small size, low power consumption, simplicity of design, and low cost. The magnetic field sensor utilizes nonlinear precession dynamics of subatomic spins to attain parametric amplification of a magnetic field. A preliminary experimental implementation of the proposed concept establishes its feasibility and can already demonstrate significant benefits over existing approaches to sensing.
G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux
6.
Kaposi's Sarcoma Associated Herpesvirus Vaccine and Methods of Making and Using Thereof
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Grow gallium-containing semi-conductor layers are grown on a substrate, wherein the gallium-containing semiconductor layers comprise AlxGayInzNvPwAsu, where 0≤x≤1, 0≤y≤1, 0≤z≤1, 0≤v≤1, 0≤w≤1, 0≤u≤1, v+w+u=1, and x+y+z=1. Dry etching of the gallium-containing semiconductor layers exposes sidewalls of the layers. Surface treatments are performed to recover from damage to the sidewalls resulting from the dry etching. Dielectric materials are deposited on the sidewalls, for example, by atomic layer deposition (ALD), to passivate the sidewalls. The resulting gallium-containing semiconductor layers have an improvement in optical efficiency as compared to gallium-containing semiconductor layers that are not subjected to the surface treatments and the deposition of the dielectric materials.
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 33/44 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the coatings, e.g. passivation layer or anti-reflective coating
An anode in an electrochemical cell includes an anode active material comprising sodium and a solid electrolyte interphase (SEI) layer disposed on the anode active material. The SEI layer includes reduction products of an electrolyte solvent and is free of degradation products derived from dissolved anions of an electrolyte salt. The electrolyte solvent and the electrolyte salt are present in an electrolyte of the electrochemical cell. The SEI layer does not include a fluorine content greater than 5 wt. %.
The present disclosure provides a composition comprising a solid support, a plurality of tethered oligonucleotides attached to the solid support, and a plurality of untethered oligonucleotides hybridized to the tethered oligonucleotides. An untethered oligonucleotide can comprise, attached via the 5′ end, a cell, or an effector molecule. Hybridization of an untethered oligonucleotide to a tethered oligonucleotide generates an enzyme cleavage site, which allows for temporally controlled removal of an effector molecule. The present disclosure provides methods of temporally modulating the activity and/or phenotype of a cell. The present disclosure provides a solid support comprising patterned tethered oligonucleotides attached thereto; and methods of making the solid support.
A method can include providing a first neural network connected to a second neural network. The first neural network can represent B+11 and the second neural network can represent electrical properties. The method can include training the first neural network and the second neural network jointly. The method can include determining, from the trained first neural network and the trained second neural network B+11, a prediction of and electrical properties at one or more predetermined locations. The method can include outputting the prediction of B+11 and EP.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The shallow neural network with multiple recurrent and redundant loop-like wave mediated neuronal connections employs amplitude weighting factors and a phase parameter represented by non-planar connection paths. The presence of non-planarity in the connection paths allows faster and more efficient computations, reduced memory demands, and enhanced learning capabilities compared to traditional multi-layer deep AI/ML neural networks.
Methods and apparatus for dispensing droplets. In accordance with an implementation, an apparatus includes a dispenser, a liquid source, and a pressure source. The dispenser includes a tube having an outlet, a channel surrounding the tube, a flow path coupling the channel and the outlet of the tube. The liquid source to be coupled to the tube and to contain a liquid and the pressure source to be coupled to the channel. The liquid is to flow from the liquid source through the tube and the pressure source is to flow gas through the channel to cause a droplet of the liquid to be dispensed from the outlet of the tube.
This disclosure provides a precision-positioning/quality control system capable of measuring the exact position of any given mechanical component/part of any size or shape used during an assembly process. In one aspect, a process for performing high-accuracy localization and positioning of a rigid object is disclosed. This process can begin by receiving a full image of the object. The full image is then processed by a deep-learning module to identify a set of regions of interest on the object. Next, the identified regions in the set of regions of interest are subsequently processed to identify a number of surface points within each identified region and accurately estimate their positions. After sequentially processing all the regions of interest, the process subsequently generates an accurate position estimation for the object based on the combined set of identified high-precision surface points for the set of regions of interest.
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
H04N 23/13 - Cameras or camera modules comprising electronic image sensors; Control thereof for generating image signals from different wavelengths with multiple sensors
H04N 23/69 - Control of means for changing angle of the field of view, e.g. optical zoom objectives or electronic zooming
H04N 23/695 - Control of camera direction for changing a field of view, e.g. pan, tilt or based on tracking of objects
H04N 23/698 - Control of cameras or camera modules for achieving an enlarged field of view, e.g. panoramic image capture
17.
METHODS AND SYSTEMS OF PREDICTING AGENT INDUCED EFFECTS IN SILICO
The disclosure presents a new computer based model framework to predict drug effects over multiple time and spatial scales from the drug chemistry to the cardiac rhythm. The disclosure presents a new computer based model framework to predict drug effects from the level of the receptor interaction to the cardiac rhythm.
G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
G16C 20/70 - Machine learning, data mining or chemometrics
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Provided are methods of modulating gene expression levels in an individual identified as having endometriosis. The methods comprise administering to the individual identified as having endometriosis a drug described herein in an amount effective to modulate gene expression levels in the individual. Also provided are pharmaceutical compositions. The compositions comprise a drug described herein in an amount effective to modulate gene expression levels in an individual, wherein the pharmaceutical composition is adapted for intrauterine or intravaginal administration of the drug to the individual. Kits that find use in practicing the methods of the present disclosure are also provided. In some embodiments, the kits comprise a pharmaceutical composition comprising a drug described herein in an amount effective to modulate gene expression levels in the individual, and instructions for administering the pharmaceutical composition to an individual identified as having endometriosis.
A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof.
The present disclosure provides methods and compositions for increasing resistance of plants to a disease caused by infection with bacteria of a Liberibacter species.
The present disclosure provides methods for producing fuels, such as biofuels, and commodity chemicals. In some embodiments, the methods comprise pretreating cellulosic biomass with a sugar acid. In some embodiments, the methods further comprise recycling sugar acids that are produced during fermentation for use in the subsequent pretreatment of cellulosic biomass. In some embodiments, the methods further comprise utilizing one or more components produced during pretreatment for subsequent fermentation. Fuels and commodity chemicals produced according to the methods of the present invention are also provided herein.
C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
22.
USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING
Disclosed herein are systems, compositions and methods for using a split dCas protein system to modify the epigenetic profile of a gene of interest. The systems, compositions, and methods are useful for modifying the epigenetic profile of a particular gene within a cell, based on the discovery that effective expression of a larger-sized recombinant protein can be successfully achieved using two separate expression cassettes each encoding a half of the protein fused with a half of an intein, utilizing the unique feature of an intein system to ultimately rejoin the two halves to form one larger fusion protein with the intein spliced out.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
National Technology & Engineering Solutions of Sandia, LLC (USA)
Inventor
Cates, Joshua W.
Choong, Woon-Seng
Brubaker, Erik
Abstract
A single photon radiation detector is designed for a particular radiation source fluence, such that an incident radiation photon strikes a scintillator monolith, creating scintillation photons, which are amplified by appropriately sized channels of photomultipliers optically coupled to the scintillator monolith. The photomultiplier output is electronically shaped into a corresponding stream of scintillation pulses (otherwise referred to as scintillation photons) that pass through a comparator to produce a bitstream of the detected scintillation photons, which is sampled into a field programmable gate array (FPGA) acting as a giga-sample transceiver to produce time-to-digital conversions, capable of producing an output data stream of 10's-of-giga-samples per second or more. Appropriate design ensures sparsity of scintillation photon arrival, so that each photon in the bitstream corresponds to a single incident scintillation photon.
A detector module is provided that can be used as part of a time-of-flight positron emission tomography (TOF-PET) system. The detector module comprises a plurality of emitter elements, each emitter element including an emitter composed of a substance that produces scintillation light and/or Cherenkov radiation in response to gamma photons and, coupled to each of two opposing ends of the emitter, a plurality of photodetectors. The height or thickness of the emitters between their coupled photodetectors is less than 20 mm (e.g., 5-15 mm). The photomultipliers may be silicon photomultipliers or SiPMs that have surface areas less than approximately 9 mm2. Due to the quantity of photodetectors, their operating locations at both ends of each emitter, and the relative thinness of the emitters, the emitter elements and the detector module provide a timing resolution better (lower) than 100 ps full width at half maximum.
Systems and methods for electrochemical hydrogen looping cells are described. Generating a pH swing can expedite carbon dioxide capture from oceanwater. Many embodiments implement electrochemical hydrogen looping cells that simultaneously produce acid via anodic hydrogen oxidation and base via cathodic hydrogen evolution to generate a pH change.
A skin-covered, linkage-driven implantable prosthesis, the prosthesis comprising a first linkage comprising a distal end and a proximal end, wherein the proximal end is configured to fixate into a first proximal bone and comprises a first hinge configured to rotate in parallel with a first proximal joint, a second linkage with a hollow center to configured to allow the first linkage to cross through and comprising a distal end and a proximal end, wherein the proximal end is configured to fixate into a second proximal bone, a second hinge attached to distal end of the first linkage and configured to imitate a second proximal joint, and a tip component configured to imitate a distal phalanx and connected to the first linkage by the second hinge and to the second linkage by a bottom hinge, wherein motion of the prosthesis is allowed through a linkage- driven mechanism.
There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
29.
FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNE
Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
30.
Wireless Recording System-on-chip for Distributed Neural Interface Systems with Inductive Power Delivery and UWB Data Transmission
Systems and method for wireless recording system-on-chips for distributed neural interface systems with inductive power delivery and UWB data transmission are described. In an embodiment, the system includes an implantable neural interface including: an electrode array having several electrodes; front end circuitry including: one or more digital components, and at least one amplifier coupled to a first electrode and a second electrode of the electrode array, wherein the amplifier and the first electrode and the second electrode form a sensing channel configured to sense electrical activity; and a transceiver including: several digital components; a power harvesting system that receives RF energy through a wireless power link; and a wireless clock receiver that provides a clock signal to the one or more digital components of the front end circuitry and the several digital components of the transceiver.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (USA)
Inventor
Roth, Theodore Lee
Marson, Alexander
Abstract
Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell.
The present invention relates to the development of and use of genetically modified human differentiated cells coupled with xenotransplantation into animal models to identify injury and disease-specific RNA and/or protein biomarkers. Specifically, the present invention encompasses two complementary methods for biomarker discovery that enable the direct and selective labelling, isolation, and analysis of human-specific RNA and/or proteins from xenotransplantation (or chimeric) animal models. Both methods involve the treatment of animal models with an RNA analog and/or amino acid analog that enables the specific isolation and quantification of human RNAs and/or proteins for the identification of novel human biomarkers for a large array of human injuries and diseases.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A01K 67/0271 - Chimeric vertebrates, e.g. comprising exogenous cells
A method includes forming a conductive material on a first dielectric layer, exposing the conductive material to aniline to produce a passivated surface of the conductive material, and after exposing the conductive material to aniline, forming a second dielectric layer on the first dielectric layer using a deposition process. The deposition process is a water-free and plasma-free deposition process, and the second dielectric layer does not form on the passivated surface of the conductive material.
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
H01L 21/67 - Apparatus specially adapted for handling semiconductor or electric solid state devices during manufacture or treatment thereof; Apparatus specially adapted for handling wafers during manufacture or treatment of semiconductor or electric solid state devices or components
34.
AUTOMATED AI/ML MANAGEMENT OF USER EXPERIENCES: SYSTEM AND METHOD
Aspects of the subject disclosure may include, for example, categorizing users of a cellular network according to a plurality of user categories, identifying, by a machine learning model, a service degradation in the cellular network, identifying at least one affected user, the at least one affected user being affected by the service degradation, identifying one or more affected user categories including the at least one affected user, identifying potentially affected users, the potentially affected users being categorized according to the one or more affected user categories, and taking action to isolate the potentially affected users from the service degradation. Other embodiments are disclosed.
H04W 24/02 - Arrangements for optimising operational condition
H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence
H04L 41/507 - Filtering out customers affected by service problems
H04W 36/30 - Reselection being triggered by specific parameters by measured or perceived connection quality data
35.
AUTOMATIC TROUBLESHOOTING SYSTEM FOR USER-LEVEL PERFORMANCE DEGRADATION IN CELLULAR SERVICES
Aspects of the subject disclosure may include, for example, training a cell-level machine learning model to predict a likelihood of a cell site in a cellular network having service issues that impact customers of the cellular network, training a user equipment (UE) level machine learning model using output information from the cell-level machine learning model and historical information about UE-level performance metrics, receiving, from a customer associated with a UE device operating on the cellular network, information about a service degradation experienced by the customer on the UE device, providing the information about the service degradation to the UE-level machine learning model; and receiving, from the UE-level machine learning model, information identifying a source of the service degradation. Other embodiments are disclosed.
H04W 24/04 - Arrangements for maintaining operational condition
H04L 41/149 - Network analysis or design for prediction of maintenance
H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence
CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LE DEVELOPPEMENT (France)
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (Germany)
Inventor
Sundaresan, Venkatesan
Khanday, Imtiyaz
Guiderdoni, Emmanuel
Mieulet, Delphine
Mercier, Raphaël
Abstract
Synthetic apomixis can be achieved in an F1 hybrid of rice by inducing MiMe mutations and egg cell expression of BBM1 in a single step, while simultaneously providing an increased efficiency of clonal seed production. This can be used to generate hybrid plants from crosses from distant subspecies parents that produce clonal seed, allowing for maintenance of heterosis in future generations.
The present disclosure provides compositions and methods for producing a crop plant or seeds of the crop plant that induce biofilm formation (e.g., biofilm comprising nitrogen-fixing bacteria), in which the crop plant or the seeds are treated with a compound of Table 1 (e.g., tannic acid).
Certain embodiments of the invention provide a synthetic genomic safe harbor in the genome of a cell. Certain embodiments provide a method of creating a synthetic genomic safe harbor in a genome. Certain embodiments of the invention provide a method of genome editing in a cell.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
39.
TEMPOROMANDIBULAR JOINT REPLACEMENT PROSTHESIS AND METHODS OF USE
Described herein are temporomandibular joint (TMJ) prosthesis (100) designs for use in animals, such as dogs and cats. The prosthesis designs include a cranial component (102) for attachment to a cranium, a mandibular component (108) for attachment to a mandible, and an articulation component. The articulation component includes a ball (116) and socket (124) joint that provides for relative movement between the cranial and mandibular components. Also described are methods of treating a mammal with the TMJ prosthesis designs.
Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L1 therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Bead constructs of sizes in the nanometer to micrometer range with a primary functionalization of a lipid membrane with embedded anchor peptides are provided. The anchor peptides may be adapted for a secondary functionalization of active molecules that are bound to the anchor peptides by transpeptidation or similar process. The functionalized bead platform can be adaptable and used in many different applications including biochemical and cellular assays, molecular diagnostics such as protein-protein interactions, protein-DNA interactions, DNA detection, separations, purifications, imaging, and microfluidics.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primate uPAR, e.g., a cynomolgus uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins and conjugates of the present disclosure to treat a condition associated with uPAR expression and/or activity are also provided. In some embodiments, the condition associated with uPAR expression and/or activity is cancer. Non-limiting examples of such cancers include those characterized by cancer cells that express uPAR on the surface thereof, cancers characterized by stromal cells in the tumor microenvironment that express uPAR on the surface thereof, and/or the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein is a method for evaluating infant suckling behavior, comprising: collecting suckling data from an infant using a vacuum measurement device, transmitting the collected suckling data to a processor, processing the collected suckling data by the processor using a pre-trained Machine Learning (ML) algorithm to identify one or more abnormalities in the infant's suckling behavior, wherein the ML algorithm has been trained on a set of training data comprising a plurality of dimensions associated with the training data, and wherein the identified one or more abnormalities are corresponding to one or more of the plurality of dimensions.
Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK, NFKB2, FOXP3, ARG1, CEBPDP, TNFα, ADAMTS4, PENK, FOSL1, DUSP1, ACTA1, AGT, ATF3, CDK1, CXCL8, SELP, VCAN, TFP12, or NR4A3 genes or any combination thereof, treatment of PCa with SELE agonists, TNFα antagonists, and/or immune checkpoint inhibitors (ICIs) are shown to be effective.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
45.
DIELECTRIC-ON-DIELECTRIC SELECTIVE DEPOSITION USING ANILINE PASSIVATION
A method includes forming a conductive material on a first dielectric layer, exposing the conductive material to aniline to produce a passivated surface of the conductive material, and after exposing the conductive material to aniline, forming a second dielectric layer on the first dielectric layer using a deposition process. The deposition process is a water-free and plasma-free deposition process, and the second dielectric layer does not form on the passivated surface of the conductive material.
C23C 16/04 - Coating on selected surface areas, e.g. using masks
C23C 16/52 - Controlling or regulating the coating process
C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the deposition of metallic material from metallo-organic compounds
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
C23C 16/44 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating
Recovering symbols from a stripped binary includes representing the stripped binary as a plurality of graph of graphs (GoG) representations, converting the plurality of GoGs into a plurality of expressive representations of each function in the stripped binary, training a machine learning (ML) model using the expressive representations, and determining a missing symbol of at least one of the functions based on an output of the ML model. Information relating to functions is and interactions between functions are used to train an ML to determine similarity of two functions. Based on similarities, missing symbols may be inferred and used to enable updates to the stripped binary file where source code is not available.
A method, a system, an apparatus, and a computer program product for determining a location of a wireless device. One or more second wireless devices in a plurality of second wireless devices are configured for processing one or more communications exchanged with a first wireless device in a plurality of first wireless devices to determine a location of the first wireless device in an environment. One or more communications are processed using one or more second wireless devices. The location of the first wireless device in the environment is determined based on the processed one or more communications.
G01S 5/02 - Position-fixing by co-ordinating two or more direction or position-line determinations; Position-fixing by co-ordinating two or more distance determinations using radio waves
G01S 5/04 - Position of source determined by a plurality of spaced direction-finders
G01S 13/76 - Systems using reradiation of radio waves, e.g. secondary radar systems; Analogous systems wherein pulse-type signals are transmitted
48.
METASURFACE, METALENS, AND METALENS ARRAY WITH CONTROLLABLE ANGULAR FIELD-OF-VIEW
A metalens and a metalens array having a bounded angular field of view are disclosed. The metalens includes a substrate and a two-dimensional (2D) grid over the substrate to divide the substrate into a 2D array of meta-units. Each meta-unit in the 2D array includes a nanostructure and a portion of the substrate that supports the nanostructure. Moreover, each meta-unit is configured with an angular-dependent transmission or reflection coefficient that decreases with an increasing incident angle of an illumination. Moreover, the metalens passes an incident light having an incident angle less than a cutoff angle and rejects an incident light having an incident angle greater than the cutoff angle. The metalens can be used a base unit for constructing a metalens array by tiling copies of the metalens into a 2D array of the metalens to achieve a significantly larger field-of-view.
A method, a system, and a computer program product for detecting and/or determining occurrence of a neurological event in a subject. Data corresponding to one or more symptoms, detected by one or more sensors, associated with a subject is received. The sensors include sensors positioned directly on the subject and/or sensors positioned away from the subject. One or more symptom values are assigned to one or more detected symptoms. A severity score for each of the symptoms is determined. The severity scores are determined using one or more machine learning models receiving the assigned symptom values as input. A prediction that the subject is experiencing at least one neurological event and at least a type of the neurological event is generated using a combination of the determined severity scores corresponding to the symptoms. A generation of one or more alerts is triggered based on the prediction. One or more user interfaces are generated for displaying the alerts.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
50.
HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION
Methods for treating diabetes are described. The methods include administration of a serotonin receptor 1F (HTR1F) antagonist, such as a substituted piperidine, methysergide, or methiothepin, to a subject in need thereof. Administration of the HTR1F antagonist can increase survival of pancreatic beta cells in conjunction with pancreatic islet transplantation. Methods for transplanting pancreatic islets to subjects such as diabetes patients are also described.
The J. Gladstone Institutes, a testamentary trust established under the will of J. David Gladstone (USA)
The Regents of the University of California (USA)
Inventor
Marson, Alexander
Mamedov, Murad
Abstract
Described herein are positive and negative regulators of BTN3A, as well as methods for identifying subjects who can benefit from T cell therapies and/or various chemotherapies. The subjects can for example be suffering from immune disorders, cancer and other diseases and conditions.
An engineered immune receptor (e.g., a chimeric antigen receptor (CAR) or chimeric costimulatory receptor (CCR)) that contains one or more short linear motifs that bind to other intracellular signaling proteins are provided, as well as nucleic acids encoding the same, cells that contain the same and methods of use. Examples of such motifs include a PLCγ1-binding motifs and TRAF binding motifs, but other motifs may be used. These motifs are thought to recruit other proteins to the engineered immune receptor, thereby altering cellular responses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
53.
ULTRASONIC MICROPHONE AND ULTRASONIC ACOUSTIC RADIO
This disclosure provides systems, methods, and apparatus related to an ultrasonic microphone and an ultrasonic acoustic radio. In one aspect a system includes a transmitter and a receiver. The receiver comprises a membrane. The membrane comprises a single layer or multiple layers of a two-dimensional material. The receiver is operable to receive sound waves in a frequency range, with the frequency range being the ultrasonic frequency range.
G01H 11/06 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by detecting changes in electric or magnetic properties by electric means
G01S 15/10 - Systems for measuring distance only using transmission of interrupted, pulse-modulated waves
G08B 1/08 - Systems for signalling characterised solely by the form of transmission of the signal using electric transmission
Provided herein are, inter alia, antibodies (e.g. humanized antibodies, monoclonal antibodies, antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 1 (ROR1) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR1-related diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates generally to methods for preparing a tissue sample for detection of the expression of a transmembrane protein in the tissue sample. The present disclosure also provides antibodies and treatments targeting tumor samples expressing the PLXDC1 or the PLXDC2 proteins.
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NatureNature 565: 91–95). The parthenogenesis efficiency by BABY BBOM1 itself is 10-29 %. This invention describes methods of high frequency of parthenogenesis by simultaneous expression of BABY BOOM and DWT1 transcription factors. When BABY BOOM1 and DWT1 are expressed together through egg cell-specific promoters, parthenogenesis efficiencies of up to 90 % are achieved. These high parthenogenesis efficiencies are a prerequisite for field applications of synthetic apomixis in crop plants.
This disclosure provides systems, methods, and apparatus related to high-temperature thermal energy storage. In one aspect, a composite material includes a ceramic and graphite flakes dispersed in the ceramic. The ceramic serves as a matrix of the composite material. The ceramic is an oxide, a carbide, a boride, or a nitride. The graphite flakes are about 20 weight % to 35 weight % of the composite material. The composite material has a porosity of about 5% to 40%.
C04B 35/52 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbon, e.g. graphite
58.
CHROMIUM AND ARSENIC SEPARATIONS USING POROUS ORGANIC FRAMEWORKS
The disclosure provides for porous organic frameworks functionalized to comprise pendant amino-dial groups and/or amino-polyol groups, and uses thereof, including for use in selectively capturing and/or separating anionic contaminants, such as chromium and arsenic oxyanions, including Cr(O), Cr(ll), Cr (III), Cr (IV), and/or Cr (VI), from other components.
Methods for analyzing the metastatic potential of circulating tumor cells (CTCs). Methods including analyzing growth signaling autonomy, methods for determining the likelihood of tumor metastases, and methods of treating a cancer determined to be likely to metastasize.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
A latent heat battery (LHB) is provided that stores latent heat for on-demand use (e.g., for conversion into electricity) and that cycles through charge and discharge cycles. In the charge cycle, a phase change material or PCM (e.g., silver) residing in an inner chamber of the battery is heated to or beyond its melting temperature, thereby storing latent heat within the battery. Illustratively, the heating may occur by collecting or focusing solar energy, or by powering an internal heater (e.g., a resistance heater). In the discharge cycle, the stored latent heat is extracted as the PCM freezes, through a heat pipe or some other construct that couples the PCM to the environment external to the LHB.
basis (additionally applicable on a population level), by analyzing how the machine-learning model responds to the input query, and outputting a prediction of model generalization for the machine-learning model based on the one or more metrics.
A core-shell particle system for performing nucleic acid amplification of targets includes particles having a hydrogel outer shell surrounding a core region that is substantially devoid of hydrogel, wherein the outer shell comprises pores having a size that permit the passage of the targets and nucleic acid reagents into the core region from an external environment surrounding the particles while substantially preventing the escape of amplicons generated in the core region in response to nucleic acid amplification. The system is used by mixing the particles with target and nucleic acid amplification reagents and partitioning the particles from one another. The particles are incubated for a period of time so as to generate amplicons. The particles are then de-partitioned from one another. The de-partitioned particles are then exposed to a dye or fluorescent reporter that is specific to nucleic acids or to a target amplicon and optically interrogated.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
64.
SYSTEMS, DEVICES AND METHODS FOR SORTING MOVING PARTICLES
Systems, devices and methods for sorting particles utilizing focus stacking of two-dimensional images are described. Such systems, devices and methods may further provide for particle processing and may encompass, on a microfluidic scale, sample enrichment, sample mixing, sample/particle sorting, verification of sorting and feedback-based optical sorting.
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Panetta, Francis Julian
Babaei, Vahid
Esfahani, Halehossadat Mohammadian
Luci, Emiliano
Prof. Seidel, Hans-Peter
Abstract
Disclosed herein is a manufacturing system (100, 300). The execution of the machine executable instructions (112) causes a computational system (104) to: receive (200) a release profile (114, 720, 722) for an object to be constructed of one or more materials; construct (202) a similarity cost function (116) dependent on a difference between a simulated release curve (118) of a trial density field (120) and the release profile for the object; construct (204) an optimization problem (122) comprising the similarity cost function and a manufacturing penalty function (124); construct (206) an optimized density field (126) by numerically solving the optimization problem to provide the trial density field that minimizes the optimization problem; and provide (210) a three-dimensional design (130, 730, 732, 734) of the object using the optimized density field that minimizes the optimization problem.
A new prune cultivar designated ‘UC G2S-8’ has been developed. The fruit of this cultivar are medium, yellow in color and covered with a grayish waxy bloom. The ‘UC G2S-8’ tree is productive and a regular bearer.
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Materials, methods, electrodes, and devices related to high-energy-density, long-life Li-ion batteries are provided. The lithium-ion anode material contains a porous core with silicon and optionally carbon nanotubes, and a dense shell made from lithium vanadium oxide having a disordered rocksalt structure. The lithium vanadium oxide functions as a solid-state mediator layer for the anode material and overcomes the well-known problem of significant volume increase when silicon is lithiated. The lithium vanadium oxide possesses mechanical robustness and prevents electrolyte penetration. For these reasons, the anode material forms a highly stable interface with the battery electrolyte. Experimental data is presented and discussed to demonstrate embodiments of the technology. It is shown that the silicon anode material can reversibly deliver a specific capacity higher than 2500 mA·h/g. The anode material exhibits excellent cycling stability and calendar life at room temperature as well as elevated temperature.
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
Aspects of the subject disclosure may include, for example, receiving, from a machine learning model, information about an event causing a service degradation in a cellular network, wherein the event is external to the cellular network, determining one or more event categories associated with the event causing the service degradation, determining, based on the one or more event categories, likely affected customers, the likely affected customers being likely to experience the service degradation, determining, by the machine learning model, proper resources for resolution of the service degradation, wherein the determining proper resources is based on the one or more event categories, and dispatching the proper resources for resolution of the service degradation. Other embodiments are disclosed.
in vivo ex vivoIn vivo In vivo imaging can include an imager and an optical front-end. Such front-ends can include a collimator and a filter. The combination can be used to reduce interference or noise coming from oblique light. Additional systems can be used for laparoscopic imaging and/or image-guided surgery, such as tumor resection.
71.
COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS
The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NF AT, NF-KB and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.
Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
73.
COLLOIDAL CRYSTAL MICRONEEDLE PATCH FOR GLUCOSE MONITORING
A minimally invasive glucose-responsive colloidal crystal microneedle (GCC-MN) patch is disclosed for naked-eye glucose monitoring. The (GCC-MN) patch is designed with a resin or polymeric core to mechanically support a shell of glucose-responsive colloidal crystal material for glucose sensing and reporting of glucose concentrations or concentration changes. The GCC-MN patch could translate the glucose concentrations into naked-eye distinguishable color changes within about 5 min, and such glucose responsiveness is reversible. Demonstrated in a type 1 diabetic mouse model, the interstitial fluid extraction, glucose sensing, and resulting glucose-relevant color display procedures are simultaneously achieved with this GCC-MN patch.
A membrane desalination system includes a housing, an electrically conductive membrane disposed within the housing, wherein the electrically conductive membrane includes a porous support and an electrically conductive layer disposed on the porous support, and the electrically conductive layer includes nanostructures, and an alternating current power source connected to the electrically conductive membrane.
B01D 65/08 - Prevention of membrane fouling or of concentration polarisation
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
Provided are compositions, methods and uses relating to one or more virus or virus-like particle(s), each of which comprises at least one epitope(s) of a pathogen causing the disease or one or more of the cholesterol checkpoint protein(s).
The subject matter disclosed herein is generally directed to pathogenic Th1 cells whose phenotype is dependent on IL-23R signaling. Th1 cell specific therapeutic targets and gene programs are disclosed herein. In particular, inhibition of CD160 reduces Th1 cell pathogenicity.
In alternative embodiments, provided are methods for treating and ameliorating a cancer such as a leukemia such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug such as dasatinib, or ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir and/or dolutegravir or any combination thereof. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug such as dastinib, or ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir and/or dolutegravir or any combination thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61M 15/08 - Inhaling devices inserted into the nose
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (USA)
Inventor
Kolodney, Michael S.
Rotunda, Adam M.
Abstract
Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/185 - Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61Q 19/06 - Preparations for care of the skin for countering cellulitis
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1) or (FX2). The polymer of formula (FX1) or (FX2) in some aspects inhibits the protein-protein interaction between VCP and mutant-type Huntingtin protein.
C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
80.
Active Agent Delivery Devices and Methods of Using the same
Provided are active agent delivery devices configured to deliver an active agent formulation into or through a mucosal layer in a subject. The active agent delivery devices include a power reservoir configured to eject the active agent formulation at a pressure sufficient to deliver the active agent formulation into or through a mucosal layer in a subject. Methods of using the subject active agent delivery devices are also provided.
The disclosure provides stable antimicrobial (e.g., antibacterial or antifungal or both) peptides (SAMPs) that can be used in methods of preventing or treating a bacterial disease (e.g., a Liberibacter disease, such as citrus greening disease (also called Huanglongbing (HLB)) or potato Zebra Chip disease, and other bacterial diseases such as those caused by Agrobacterium tumefaciens (also known as Rhizobium radiobacter) and Pseudomonas syringae) in plants (e.g., citrus plants or potato plants).
in vitroin vivoin vivoin vivoin vivo, or by administering to an individual in need thereof T cells (such as CAR T cells) genetically manipulated to have increased XCL1 polypeptide expression.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
83.
PIEZOELECTRIC MICROMACHINED ULTRASONIC TRANSDUCERS FOR BLOOD PRESSURE MONITORING
Methods and compositions for rejuvenating cells are provided. In certain aspects, the method includes increasing, in the cells, the activity of one or more of the transcription factors (TFs) presented herein. In certain aspects, the method includes decreasing, in the cells, the activity of one or more of the TFs presented herein. In certain aspects, the method includes increasing activity of one or more and decreasing the activity of one or more of TFs presented herein
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
86.
SYSTEMS AND METHODS FOR CONTROLLING AND ENHANCING IMMUNE CELL SIGNALING
Systems and methods for activating immune cells are described. Immune cells can be activated using IgG bound with antigen or via light and light sensitive peptides. An immune cell can be genetically manipulated to express a light sensitive peptide. Light is illuminated on the immune cell to activate it. The light sensitive peptide includes a means for locating to the cellular membrane, an activating domain, and a clustering domain that is responsive to light. Systems and methods for controllably inducing antibody-dependent phagocytosis are also described.
A pulsed magnetic particle imaging system includes a magnetic field generating system that includes at least one magnet, the magnetic field generating system providing a spatially structured magnetic field within an observation region of the magnetic particle imaging system such that the spatially structured magnetic field will have a field-free region (FFR) for an object under observation having a magnetic nanoparticle tracer distribution therein. The pulsed magnetic particle imaging system also includes a pulsed excitation system arranged proximate the observation region, the pulsed excitation system includes an electromagnet and a pulse sequence generator electrically connected to the electromagnet to provide an excitation waveform to the electromagnet, wherein the electromagnet when provided with the excitation waveform generates an excitation magnetic field within the observation region to induce an excitation signal therefrom by at least one of shifting a location or condition of the FFR. The pulsed magnetic particle imaging system further includes a detection system arranged proximate the observation region, the detection system being configured to detect the excitation signal to provide a detection signal. The excitation waveform includes a transient portion and a substantially constant portion.
A method to upregulate CD46 cell surface expression and combination therapies for various cancers employing an anti-CD46 antibody and an immunomodulatory imide drug (IMiD) or a Signal Transducer And Activator of Transcription 3 (STAT3) inhibitor or both are provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides CRISPR-Cas effector polypeptides that exhibit enhanced gene editing and/or trans cleavage activity, compared to a wild-type CasPhi polypeptide. The present disclosure provides systems and kits comprising such CRISPR-Cas effector polypeptides. The present disclosure provides methods, including gene editing and diagnostic methods, using a CRISPR-Cas effector polypeptide of the present disclosure.
The invention provides a catalyst comprising 1) Ru0 and 2) Pd0, Pt0, Rh0, or Ir0, on a solid support. The catalyst is useful for water purification applications. In particular, the catalyst is useful for reducing ClO3− and ClO2− from water. The invention also provides catalysts that are useful for reducing nitrate in a water supply and methods for their use.
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventor
Rodriguez, Alberto
Meadows, Jamie A.
Sun, Ning
Simmons, Blake A.
Gladden, John M.
Abstract
The present invention provides for a method for producing a 4-vinylphenol (4VP) and/or 4-vinylguaiacol (4VG), the method comprising: (a) providing a host cell capable of expressing a polypeptide having a phenolic acid decarboxylase (PAD) enzymatic activity wherein the polypeptide is capable of converting p-coumaric (CA) and/or ferulic acid (FA) into 4-vinylphenol (4VP) and/or 4-vinylguaiacol (4VG), respectively; and (b) culturing the host cell in a culture medium to express the polypeptide such that the polypeptide converts CA and/or FA into 4VP and/or 4VG, respectively; wherein the culture medium comprises an organic overlay or phase.
344 precursor powders with lower molar percentages of NaCl resulting in a composition with reduced or no-crystallinity and an increased concentration of Na vacancies.
H01M 10/05 - Accumulators with non-aqueous electrolyte
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
93.
MINIATURE MAGNETIC SHIELDS WITH MAGNETIC THROUGH SUBSTRATE VIAS
One or more embodiments relate to custom microfabricated magnetic shields that are configured to provide isolation of superconducting electronics (SCE) circuits/chips from each other and an external environment. Whereas most superconducting circuits require magnetic shielding and most shields work by fully encapsulating the circuits, leaving little access for quite rigid and fragile fibers, one or more embodiments allow custom magnetic shield shapes to be fabricated. The shield design can depend upon the particular application, and many variations are possible. For example, in an optical interconnect application, the design can depend on whether an active (VCSEL) or passive photonic (grating/edge coupled) scheme is selected — a flexible solution is provided that supports both techniques. The shields can be created by depositing a monolithic layer conformally in a pit that has been fabricated in a silicon substrate. In embodiments, to improve the shielding, magnetic vias composed of permalloy can be introduced into the shield design. The vias can connect the magnetic shield to a permalloy layer beneath the silicon substrate.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
95.
SYSTEMS AND METHODS FOR FULLY WIRELESS AND BATTERYLESS LOCALIZATION AND PHYSIOLOGICAL MOTION DETECTION
A battery-less, wirelessly powered localization system is described. In an embodiment, a wirelessly powered localization system, includes an external Tx antenna that generates a radio frequency (RF) signal that wirelessly powers a set of one or more localizers, an external Rx antenna that receives an output from the localizers, a localizer including: an Rx antenna that receives a radio frequency (RF) signal from an external Tx antenna, a passive four-stage full-wave CMOS rectifier that generates a DC voltage using the received RF signal, a low-dropout regulator that generates a stable DC voltage based on the rectifier-generated voltage, a frequency divider circuit to divide the frequency of received RF signal, and a Tx antenna that outputs an RF signal at the divided frequency to the external Rx antenna.
A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
G01S 1/02 - Beacons or beacon systems transmitting signals having a characteristic or characteristics capable of being detected by non-directional receivers and defining directions, positions, or position lines fixed relatively to the beacon transmitters; Receivers co-operating therewith using radio waves
96.
COVALENT, CHEMOGENETIC ACTIVATORS FOR K2P POTASSIUM CHANNELS AND USES THEREOF
Disclosed herein are, inter alia, activators of K2P potassium channels and pharmaceutical compositions thereof, and methods comprising their use for the treatment of diseases or adverse conditions related to low TREK family protein activity.
Aspects of the disclosure relate to antibodies and methods of use. Various antibodies are disclosed, including engineered antibodies targeting CD138, CD38, and TfR1. Certain aspects are directed to IgE antibodies and use in diagnosis and/or treatment of cancer. Also disclosed are kits and pharmaceutical compositions comprising one or more engineered antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Described herein is an implantable device comprising a radiation-sensitive element (such as a transistor) configured to modulate a current as a function of radiation exposure to the transistor; and an ultrasonic device comprising an ultrasonic transducer configured to emit an ultrasonic backscatter that encodes the radiation exposure to the transistor. Further described herein is an implantable device comprising a radiation-sensitive element (such as a diode) configured to generate an electrical signal upon encountering radiation; an integrated circuit configured to receive the electrical signal and modulate a current based on the received electrical signal; and an ultrasonic transducer configured to emit an ultrasonic backscatter based on the modulated current encoding information relating to the encountered radiation. Further described are systems including one or more implantable devices and an interrogator comprising one or more ultrasonic transducers configured to transmit ultrasonic waves to the one or more implantable devices or receive ultrasonic backscatter from the one or more implantable devices. Also describe are computer systems for operating implantable devices, methods of detecting radiation, methods of treating a solid cancer in a subject, and methods of monitoring a subject for recurrence of a solid cancer.
B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
A composition of matter useful as a bioadhesive including a bistable adhesive polymer. The bistable adhesive polymer includes one or more polymer backbones; side-chains attached to each of the polymer backbones; and one or more transition temperatures between a crystalline state and an amorphous state. The one or more transition temperatures are such that the polymer transitions from the crystalline state to the amorphous state upon physical contact with biological tissue having a temperature higher than the transition temperature. The polymer adheres or attaches to the biological tissue in the amorphous state and can be peeled from the biological tissue when cooled below the transition temperature to the crystalline state.
